Observational Study for over 300 patients (July 2020)
Dose Finding study (October 2020)
Phase IIB clinical trial (planned 2021)
Double blind placebo controlled study
60 patients per groupa
Chronic Pain Group
Setup unique desktop extraction units to run R&D trials on hemp and cannabis
Focus on understanding flower yield of extraction for more volatile and less prominent cannabis compounds that Cymra is focused on for pain, inflammation, sleep and anxiety.
6 compounds, including terpenoids, flavonoids and cannabolic acids found in cannabis are to be studied in synergy using various combinations.
Initial focus on cell culture inflammation models to understand amounts per compound required for highest efficacy.
Assessing “entourage effect”
We have completed our first crosses in our greenhouse
SCU have imported a collection of plants from a gene bank in Germany known as IPK.
SCU will grow the lines out undertake tests of 48 varieties to establish cannabinoid content, terpene, flavinoid and acid composition.
This project will give Cymra a diverse set of genetics and understanding of those genetics to start targeted crossings
The development of protocols to initiate, micro propagate and maintain cannabis in Tissue Culture
Establishment of callus and shoot regeneration (pre cursor work to gene editing/advanced breeding)
Establishment of transformation protocols (pre cursor work to gene editing/advanced breeding)
Medical Cannabis Information and Updates
Want to keep up to date with the latest Medical Cannabis Information in Australia and from around the world? We will send you informative information from time to time so you can learn about cannabis and if it can help you.